BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights

  Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ended March 31, 2022, along with a corporate update.

  May 12, 2022

   · 

  13 min read
• Business

  Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported pipeline and business progress and first quarter 2022 financial results.

  May 12, 2022

   · 

  8 min read
• Business

  TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

  TCR² Therapeutics Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

  May 12, 2022

   · 

  12 min read
• Business

  RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

  RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced financial results and business highlights for the three months ended March 31, 2022.

  May 12, 2022

   · 

  18 min read
• Business

  Lannett Enters Agreement to Be Exclusive U.S. Distributor of Fludarabine Phospate for Injection, USP

  Lannett Company, Inc. announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials.

  May 12, 2022

   · 

  3 min read
• Business

  Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced financial results for the first quarter ended March 31, 2022.

  May 12, 2022

   · 

  9 min read
• Policy

  LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

  LAVA Therapeutics N.V. announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for LAVA-051, the Company’s lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

  May 12, 2022

   · 

  4 min read
• Drug Development

  MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

  MediWound Ltd. announced positive results from its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers.

  May 12, 2022

   · 

  14 min read
• Business

  Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results

  Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its first quarter 2022 operating and financial results.

  May 12, 2022

   · 

  8 min read
• Business

  Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  Aadi Bioscience, Inc. today announced financial results for the first quarter of 2022 and provided a corporate update.

  May 12, 2022

   · 

  20 min read